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Abstract
Background: Human respiratory syncytial virus (HRSV), and to a lesser extent human metapneumovirus (HMPV) and human
parainfluenza virus type 3 (HPIV3), re-infect symptomatically throughout life without antigenic change, suggestive of
incomplete immunity. One causative factor is thought to be viral interference with dendritic cell (DC)-mediated stimulation
of CD4+ T cells.
Methodology, Principal Findings: We infected human monocyte-derived DC with purified HRSV, HMPV, HPIV3, or influenza
A virus (IAV) and compared their ability to induce activation and proliferation of autologous CD4+ T cells in vitro. IAV was
included because symptomatic re-infection without antigenic change is less frequent, suggesting that immune protection is
more complete and durable. We examined virus-specific memory responses and superantigen-induced responses by
multiparameter flow cytometry. Live virus was more stimulatory than inactivated virus in inducing DC-mediated
proliferation of virus-specific memory CD4+ T cells, suggesting a lack of strong suppression by live virus. There were trends
of increasing proliferation in the order: HMPV,HRSV,HPIV3,IAV, and greater production of interferon-c and tumor
necrosis factor-a by proliferating cells in response to IAV, but differences were not significant. Exposure of DC to HRSV,
HPIV3, or IAV reduced CD4+ T cell proliferation in response to secondary stimulus with superantigen, but the effect was
transitory and greatest for IAV. T cell cytokine production was similar, with no evidence of Th2 or Th17 skewing.
Conclusions, Significance: Understanding the basis for the ability of HRSV in particular to symptomatically re-infect without
significant antigenic change is of considerable interest. The present results show that these common respiratory viruses are
similar in their ability to induce DC to activate CD4+ T cells. Thus, the results do not support the common model in which
viral suppression of CD4+ T cell activation and proliferation by HRSV, HMPV, and HPIV3 is a major factor in the difference in
re-infectability compared to IAV.
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Introduction
Human respiratory syncytial virus (HRSV) is the most
important viral agent of serious pediatric respiratory tract disease
worldwide [1,2,3,4,5]. HRSV also can cause serious disease in the
elderly and in immunosuppressed individuals [6]. Among the
pediatric respiratory viruses, human parainfluenza virus type 3
(HPIV3) is the second most important cause of serious disease
[7,8], followed by human metapneumovirus (HMPV), which was
first described in 2001 [9]. Similar to HRSV, HMPV is now
recognized as an important agent of respiratory tract disease
worldwide, especially in the pediatric and elderly populations
[10,11]. By contrast, the orthomyxovirus influenza A virus (IAV)
causes serious disease in children and adults with the greatest
burden of mortality being in the elderly [12].
These common human respiratory viral pathogens share a
tropism for the superficial epithelial cells of the respiratory tract,
although IAV appears to be much more cytopathic and also
efficiently infects underlying cells in the epithelium [13,14]. All
four viruses cause acute infections with overlapping spectra of
disease symptoms. Resolution of infection and protection against
re-infection by these viruses are mediated by a similar array of
immune mechanisms involving innate immunity, serum and
secretory antibodies, and T cellular immunity. HRSV, however,
is unusual (i) in its ability to efficiently infect and cause serious
disease very early in life, with the peak of hospitalization at 2
months of age, and (ii) in its ability to readily re-infect throughout
life without need of antigenic change. HMPV and HPIV3 also can
cause serious disease in infancy, but not as early in life or as
frequently as HRSV. HMPV and HPIV3 also can re-infect
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efficiency and severity than HRSV. In contrast, IAV differs from
HRSV, HMPV, and HPIV3 in that infection usually induces long-
lasting protection such that symptomatic re-infection is dependent
on significant antigenic change. Finally, serious infection with
HRSV during infancy is associated with more severe sequelae
compared to these other viruses, including increased airway
reactivity that can persist through childhood as well as possible
links to asthma. These unusual features of HRSV epidemiology as
compared to HMPV and HPIV3, in particular the greater
frequency of infection and re-infection, are widely interpreted as
evidence that HRSV has the ability to suppress or subvert the host
adaptive immune response.
Conventional or myeloid dendritic cells (DC) are pivotal in
initiating the adaptive immune response. Immature DC reside in
peripheral tissue to capture antigen, and serve as sentinels to detect
local infection, and in lymphatic tissue, where they encounter
microbial macromolecules from the draining lymph. In addition,
during a lower respiratory tract infection, the number of DC in
bronchi and lung increases by chemotactic influx of precursors
that originate primarily from circulating monocytes [15,16,17].
After pathogen recognition, the immature DC up-regulate
major histocompatibility (MHC) and co-stimulatory molecules,
express cytokines, and shift expression of chemokine receptors to
direct the DC to the T lymphocyte-rich areas of lymphoid tissue.
This process of DC maturation may be affected by additional cues
from the infected tissue, such as cytokines produced by infected
cells, immune cells, or dying cells. A major role of mature DC is to
present antigen and activate CD4+ and CD8+ T cells such that
they proliferate and are polarized into memory and/or effector
subsets [18,19,20].
Naı ¨ve CD4+ T cells can differentiate into T helper (Th) subsets
with distinct functions and effects on the adaptive immune
response (reviewed in [21,22,23]). Four major CD4+ cell helper
subsets are currently recognized, Th1, Th2, Th17, and follicular
Th (TFH) [22,24,25]. Each of these subsets has signature cytokines.
For example, for Th1 cells, the signature cytokine is interferon
(IFN)-c; for Th2 cells, it is IL-4; and for Th17 cells, it is IL-17A.
Other cytokines may be expressed by each subset. For example,
Th1 cells may also express Tumor necrosis factor (TNF)-a [26,27].
Each of these subsets is to some extent self-stimulatory and
reciprocally inhibitory [21,23]. During re-infections, CD4+ T cell
proliferation originates largely from antigen-specific memory
CD4+ T cells that persist from the previous infection(s) and are
re-activated by antigen-presenting DC [26,28,29].
Previously, we compared the effects of HRSV, HMPV, and
HPIV3 on the maturation of human adult immature monocyte-
derived DC in a side-by side ex-vivo study and found that each virus
induced moderate, sub-maximal levels of MDDC maturation and
cytokine/chemokine responses, without evidence of virus-specific
impairment of MDDC maturation [30]. Although MDDC are not
primary human DC, DC derived from primary human monocytes
represent an appropriate model for lung DC, since monocytes give
rise to myeloid DC in the resting lung [31] as well as to mucosal
DC [32]. This is relevant to the immune response to HRSV that
occurs in pulmonary mucosa [33]. MDDC generated using IL-4
and GMCSF treatment might not entirely match DC from the
inflammatory environment of the lung, but they are phenotypi-
cally and functionally similar to DC located at sites of
inflammation in vivo [34].
In the present study, we continue this analysis by measuring the
ability of these viruses to induce proliferation and cytokine
production by autologous CD4+ T cells. Because IAV induces
stronger and more long lasting protection against symptomatic re-
infection, we used this virus as a comparator to the three
paramyxoviruses.
The T cell responses we investigated were those specific to the
respective virus-derived antigens, which primarily represent
stimulation of memory T cells from prior natural infection, and
responses to the superantigen SEB, as a model of the effect of each
virus on secondary T cell stimulation. In response to virus
stimulation of MDDC, we found a strong virus-specific T cell
proliferative response for each of the four viruses, with the
response to IAV being somewhat (but not significantly) greater
than that to HRSV and HMPV. In response to SEB secondary
stimulation, T cell proliferation was transiently reduced in T cell
cocultures with virus-matured MDDC, with the effect being
greatest for IAV. Differences in the spectrum and quantity of
cytokine production between the viruses were minimal. Thus,
while these common respiratory viruses had an inhibitory effect on
CD4+ T cell responses under certain conditions, the effect was not
profound and unlikely to account for the ability of a virus to re-
infect in nature since the effect was greatest for IAV.
Results
Comparison of the ability of human MDDC stimulated
with rHRSV, rHMPV, rHPIV3, or IAV to induce proliferation
of autologous CD4+ T cells
DDAO-labeled immature MDDC were mock-treated or treated
for 4 to 6 h with rHMPV, rHRSV, rHPIV3, or IAV, an equivalent
amount of each UV-inactivated virus, or, as a positive control, SEB.
The MDDC were then washed extensively and co-cultured with
autologous CFSE-labeled CD4 T lymphocytes at an MDDC-to-T
cell ratio of 1:10. Afteran incubationperiodof upto 7 days, the cells
were stimulated with PMA and ionomycin and harvested, stained
for discrimination between live and dead cells and immunostained
for CD3 and several cytokines. CD4 T cells were analyzed by flow
cytometry (see Figure 1 for the general scheme) to evaluate (i)
proliferation, which was scored by dilution of CFSE dye that occurs
with cell division (Figure 2), and (ii) cytokine production, measured
by intracellular cytokine staining (Figure 3).
To determine the optimal time point for T cell analysis, we
examined a time course of CD4+ T cell proliferation during co-
culture with MDDC that had been exposed to mock-treatment,
SEB, or a subset of the viruses, namely live or UV-inactivated
rHRSV or IAV (Figure 2 A and B), using cells from one donor.
CD4+ T cell proliferation was first detectable on day 2 in co-
cultures with SEB-treated MDDC, and on days 4–5 with virus-
stimulated MDDC, and continued to increase until day 6 or 7,
respectively. As expected, mock treated MDDC induced a very
low level of CD4+ T cell proliferation (,0.2%), while SEB-treated
MDDC induced the strongest proliferative response (87.6% at day
6). Among the virus specific responses, IAV-stimulated MDDC
induced more CD4+ T cell proliferation (42.3% at day 7) than
rHRSV-stimulated MDDC (34.2% at day 7), and UV-rHRSV-
and UV-IAV-stimulated MDDC induced less proliferation (15.7
and 1.1% at day 7, respectively) than their live virus-stimulated
MDDC counterparts. Proliferation was very low for cultures with
UV-IAV-treated MDDC in this particular experiment, but cells
from other donors proliferated in response to UV-inactivated virus
to a greater extent (see Figure 2 C).
Using cells from one donor, we investigated whether the
proliferating CD4+ T cells in the co-cultures with virus-stimulated
MDDC were naı ¨ve or virus specific memory CD4+ T cells: this
was determined on day 4, when proliferating cells were first
evident, and also on day 7 (Figure S1). At day 4, for each virus, 92
to 95% of the cells expressed CD45RO and not CD45RA,
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PLoS ONE | www.plosone.org 2 November 2010 | Volume 5 | Issue 11 | e15017Figure 1. CD4+ T lymphocyte gating strategy. DDAO-labeled immature MDDC were exposed to virus or controls for 4–6 h, co-cultured for up to
1 week with autologous purified CSFE-labeled CD4+ T cells, and stimulated with PMA and ionomycin prior to staining for flow cytometry. Dead cells
were excluded using a live/dead stain and MDDC were excluded based on the DDAO tracer (a). T cells were identified by gating on CD3+ cells (b).
Single cells were identified using forward scatter height (FSC-H) and forward scatter area (FSC-A) to analyze cell size (c). Remaining debris was
removed using FSC-A to analyze size and side scatter (SSC-A) to analyze cell complexity (d). Proliferating T cells were quantified by gating on CFSE to
monitor the dilution of this tracer that occurs with cell division (e; proliferated cells are boxed). Live, proliferating, singlet CD3+ cells were analyzed for
the expression of IFN-c (f), IL-4 (g), and TNF-a (h). Boolean gating was used to quantify subsets listed at the bottom.
doi:10.1371/journal.pone.0015017.g001
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PLoS ONE | www.plosone.org 3 November 2010 | Volume 5 | Issue 11 | e15017Figure 2. Proliferation of CD4+ T cells in response to autologous MDDC after exposure to SEB or purified virus. (A) Time course of
CD4+ T cell proliferation in response to MDDC that were mock-treated or treated with SEB, rHRSV, or IAV, using cells from a single donor. Days of co-
culture are indicated to the left. Proliferated cells are boxed, and their percentage relative to the total live population is indicated. (B) Line graphs of
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cells. For each virus, about 50 to 60% of these CD45RO memory
cells also expressed CCR7, a marker specific for central memory
CD4+ T cells, whereas the remaining 40% to 50% did not express
CCR7, which is typical for effector memory T cells. This indicates
that the first proliferating cells in the co-cultures were memory
rather than naı ¨ve cells, with a somewhat greater representation of
central memory versus effector memory cells. On day 7, the
proliferating CD4+ T cells were almost exclusively memory
CD45RO+ cells, with a higher proportion of effector memory cells
as compared to central memory cells (70% versus 30%).
Next, using cells from eight donors, we compared the level of
CD4+ T cell proliferation in response to MDDC exposed to each of
the four live or UV-inactivated viruses (rHMPV, rHRSV, rHPIV3,
or IAV), or SEB, or mock-treatment (Figure 2 C). The cultures were
assayed during the exponential phase of proliferation, on day 7,
when the number of proliferating cells and the difference between
live and UV-viruses was maximal. Again, mock-infected MDDC
induced minimal levels of CD4+ T cell proliferation (median of
0.4% of proliferated cells), and SEB-treated MDDC induced
maximal proliferation (median of 93.1%). With MDDC that had
been stimulated with live virus, the percentage of divided CD4+ T
cells increased in the order rHMPV , rHRSV , rHPIV3 , IAV
(medians 12.4%, 23.8%, 30.6%, and 42.2%, respectively), although
none of the differences among any of the groups was statistically
significant. MDDC stimulated with IAV, rHPIV3, or rHRSV
induced significantly more CD4+ T cell proliferation than mock-
stimulated MDDC, whereas MDDC stimulated with rHMPV did
not. MDDC treated with each of the four UV-inactivated viruses
inducedproliferation(median from 5.5%for UV-rHMPVto 12.6%
for UV-rHRSV), but to a lower extent than the live-virus-treated
MDDC counterparts, although the differences were not statistically
significant. In separate experiments, using cells from four different
donors, there was no significant CD4+ T cell proliferation during
thefirst24 h of incubationwithMDDC stimulated withSEBorany
oftheliveorUV-inactivated virusesormock-treatment (not shown).
Cytokine production by CD4+ T cells proliferating in
response to MDDC stimulated with rHRSV, rHMPV,
rHPIV3, or IAV
In addition to measuring proliferation with CFSE, we also
measured CD4 T cell cytokine expression by blocking protein
export with brefeldin A and staining for IFN-c (Th1 cytokine), IL-
4 (Th2 cytokine), IL-17 (Th17 cytokine), IL10 (immunosuppressive
cytokine) and TNF-a (pro-inflammatory cytokine). In experiments
employing cells from six donors, there were only minimal numbers
of IL-4 or IL-17 producing cells at any time point (not shown) and
a pilot experiment with cells from one donor, we detected only
minimal numbers of IL10 producing cells. Therefore, we focused
on the production of two Th1 cytokines IFN-c and TNF-a.
From the same experiment shown in Figure 2 A and B, we
analyzed the kinetics of cytokine production. In co-cultures with
SEB-treated MDDC, the number of IFN-c-positive CD4+ T cells
increased from day 2 to day 4 and then decreased through day 7
(Figure 3 A). In co-cultures with MDDC stimulated with live or
UV-inactivated IAV or HRSV, the number of IFN-c-positive
CD4+ T cells increased from day 3 to day 7, with the number of
IFN-c-producing cells being higher in response to live versus UV-
inactivated virus (Figure 3 A). The response of TNF-a-positive
cells followed a similar pattern. Figure 3 B shows a more detailed
analysis of the proliferating CD4+ T cells that produced IFN-c,
and/or TNF-a, with cytokine expression presented as a percent of
total proliferating cells. Figure 3 A and B show that, while the total
number of cytokine-positive cells in cultures with virus-treated
MDDC continued to increase through day 7 (Figure 3 A), the
subset of the total proliferating cells that produced cytokines
peaked on day 4 and decreased thereafter (Figure 3 B). Except on
day 5, when a very low number of TNF-a+ cells were detected in
the CD4+ population of this particular donor, co-cultures with
rHRSV or IAV were quite similar with regard to the total number
and the percentage of T cells expressing IFN-c and/or TNF-a.
We then analyzed cytokine production on day 7 from five of the
eight donors from the experiment shown in Figure 3 C. There
were no significant differences between the viruses with regard to
the extent of cytokine production or the Th1-biased nature of the
memory CD4+ T cell response. The percentages of TNF-a
positive and IFN-c/TNF-a double-positive cells also were similar
in response to MDDC treated with the various viruses. Also, the
median fluorescence intensities (MFI) of T cells stained for IFN-c
and TNF-a were similar, showing that MDDC treated with each
of the viruses were similar in their ability to induce IFN-c and
TNF-a production in proliferating CD4+ T cells (Figure 3 D).
Interestingly,the IFN-c MFIwas approximately two to three-fold
greater in T cells that produced both IFN-c and TNF-a, compared
to cells that produced only IFN-c. Similarly, TNF-a production was
also higher in double positive cells than in single positive cells. In
particular, IAV and rHRSV treated MDDC induced more TNF-a
in double positive T cells than SEB, rHPIV3, and rHMPV (Figure 3
D). The finding that cells that express more than one cytokine have
a higher level of expression has been noted previously for several
other viral systems [35]. The percentage of cells expressing one or
both cytokines and the intensity of expression are indicative of the
quality of the memory CD4+ T cell response: in this regard, the
responses induced by rHRSV, rHMPV, rHPIV3 were similar,
whereas the response to IAV tended to be stronger.
Effect of rHRSV, rHMPV, rHPIV3, and IAV treatment of
MDDC on non-specific CD4+ T cell proliferation in
response to SEB
It was previously reported that HRSV and HPIV3 suppress T
cell responses to secondary stimuli [36,37,38,39,40]. We investi-
gated whether this inhibitory effect is specific to HRSV and
HPIV3, or is a more general property of these acute respiratory
viruses. We used the superantigen SEB as the secondary stimulus,
as also was done in previously published studies [36,38,41,42].
Immature MDDC were mock-stimulated or stimulated for 4 to
6 h with rHMPV, rHRSV, rHPIV3, IAV or their UV-
counterparts. The MDDC were then co-cultured with autologous
CFSE-labeled CD4+ T lymphocytes in presence of SEB to drive
non-specific T cell proliferation. The concentration of SEB was
reduced from 1 mg/ml to 50 ng/ml, in an attempt to avoid
overcoming possible viral effects.
As with the previous set of experiments, we first determined the
best time point to measure proliferative and cytokine responses
the data from panel A. (C) Summary of CD4+ T cell proliferation in experiments using cells from eight donors in which MDDC were mock-treated, or
treated with each of the four live or UV-inactivated viruses or SEB, with proliferation measured following 7 days of co-culture. Each donor is
represented by a unique symbol. The median percent proliferation for each condition is indicated by a horizontal line. Treatments sharing the same
lowercase letter do not differ significantly at P#0.05 (Friedman test with Dunns post hoc test (see Materials and Methods).
doi:10.1371/journal.pone.0015017.g002
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SEB in combination with mock-treated MDDC resulted in a
strong proliferation of CD4+ T cells (89.1% on day 6).
Surprisingly, strong T cell proliferation also was observed by day
6 in response to MDDC that had been stimulated with virus prior
to co-culture in the presence of SEB (86.3%, 90%, and 80.3% for
rHRSV, UV-rHRSV, and IAV, respectively). Examination of
earlier time points, however, indicated that there was a delay in T
cell proliferation for the virus-stimulated cultures. Specifically,
when compared to mock-pre-treatment, there was substantially
less T cell proliferation on days 3, 4 and 5 in co-cultures with live
rHRSV- and IAV-stimulated MDDC and, to a lesser extent, with
UV-rHRSV-stimulated MDDC. Thus, exposure of MDDC to
virus had an inhibitory effect on non-specific proliferation in
response to SEB, but the inhibition of secondary proliferation by
any of the respiratory viruses used for this study was transient, and,
at least for this single donor, was not substantially different
between the different viruses.
Next, using cells from six donors, we compared the level of
CD4+ T cell proliferation in response to MDDC that had been
mock-treated to those stimulated with each of the four live or UV-
inactivated viruses (rHMPV, rHRSV, rHPIV3, or IAV) followed
by co-culture in the presence of SEB (Figure 4 C). This
comparison was made on day 4, the time point where prior virus
treatment had the greatest inhibitory effect on CD4+ T cell
proliferation in response to SEB. This showed that, compared to
mock-treated MDDC, the proliferation was reduced by 22%, 29%
and 52% by live rHRSV, rHPIV3 and IAV, respectively. T cells in
co-cultures with rHMPV-stimulated MDDC proliferated in
response to SEB to the same extent as those in co-cultures with
mock-treated MDDC. Thus, based on the median of the responses
of the six donors, rHMPV did not appear to have an inhibitory
effect, whereas inhibition of T cell proliferation was slight for
rHRSV and rHPIV3 and greatest with IAV. In contrast, and
consistent with our previous report [36], none of the UV-
inactivated viruses had significant anti-proliferative effects.
We previously reported that types I and III (lambda) IFN play a
role in the inhibition of CD4+ T cell proliferation in response to
HRSV-exposed MDDC [36]. Therefore, we asked whether
adding IFN-b (which is the earliest type I IFN released from
MDDC following stimulation by the whole panel of viruses [30]),
IL-28A (IFN-l2), or IL-29 (IFN-l1), individually or combined,
during co-culture might affect proliferation in response to SEB.
Figure 4 C shows that among six donors, IFN-b (added at 75 IU/
ml, a concentration representative of that detectable after exposure
of MDDC to virus [30]) resulted in a significant 19% reduction of
proliferation in response to SEB (P#0.05 as compared to mock-
treated MDDC). For three of the 6 donors, mock-treated MDDC
were also co-cultured with CD4+ T cells in the presence of IL-28A
or IL-29, or IL-28A, IL-29, and IFN-b together. We found that
the type III interferons have limited, if any, additional suppressive
effects.
Effect of rHRSV, rHMPV, rHPIV3, or IAV treatment of
MDDC on cytokine expression by CD4+ T cells
proliferating in response to SEB
As part of the experiments described in the previous section,
proliferating CD4+ T cells were analyzed by intracellular cytokine
staining to quantify expression of IFN-c, IL-4, IL-17 and TNF-a.
Since there was minimal detection of cells producing IL-17 at any
time point (data not shown), we focused on the production of IL-4,
IFN-c and TNF-a. However, IL-4+ cells that were detected were
also IFN-c+ and TNF-a+ (Figure 5A). The proportions of single
IL-4 positive cells were very low and are not shown.
From the experiments shown in Figure 4 A and B, we analyzed
the time course of cytokine production by proliferating CD4+ T
cells, during co-culture in the presence of SEB, with MDDC that
had been treated with live or UV-inactivated rHRSV, IAV, or
mock treatment. In co-cultures of mock-treated MDDC and T
cells with SEB, the fraction of proliferating T cells that expressed
IFN-c and/or TNF-a increased up to day 3 and then decreased
thereafter (Figure 5 A). The time course of cytokine expression by
proliferating T cells was nearly identical when co-cultured with
UV-rHRSV-stimulated MDDC in presence of SEB. By contrast,
live rHRSV modestly decreased the fraction of cytokine-producing
cells on day 3, and modestly increased that fraction on day 5. IAV
decreased the fraction of cytokine-producing cells on days 2–4.
Thus, both live viruses effected a reduction in the fraction of
cytokine-producing cells, especially on day 3, and the effect was
greater for IAV than for rHRSV.
We then analyzed CD4+ T cell cytokine expression in the
experiments shown in Figure 4 C, using cells from six donors and
MDDC that were mock-stimulated or stimulated with each of the
four live or UV-inactivated viruses (rHMPV, rHRSV, rHPIV3, or
IAV) and then co-cultured in the presence of SEB (Figure 5 B and
C). Cytokine expression by proliferating CD4+ T cells was assayed
on day 4, the time point where prior virus treatment had the
greatest inhibitory effect on CD4+ T cell proliferation in response
to SEB (Figure 4 A). In general, the differences between the
various treatments were minor. The median percentage of T cells
expressing IFN-c and/or TNF-a was similar for co-cultures
containing MDDC that were initially mock-treated or stimulated
with any of the UV-inactivated viruses. Thus, the response to the
secondary SEB stimulation was not significantly affected by any of
the UV-inactivated viruses. In the case of co-cultures with MDDC
that were stimulated with live virus prior to the secondary SEB
stimulation, the median percentages of cytokine-producing CD4+
T cells were not significantly different for rHRSV and rHMPV
(and rHPIV3, except for TNF-a) versus mock-treatment (Figure 5
B). In the case of IAV, there was a significant reduction in the
percentage of T cells expressing TNF-a, or both TNF-a and IFN-
c, as compared to mock. In addition, IAV reduced the IFN-c and
TNF-a MFIs in the IFN-c+ and TNF-a + single positive
population, respectively (Figure 5 C). Thus, overall, the response
to secondary SEB stimulation was not significantly affected by
Figure 3. Cytokine expression by CD4+ T lymphocytes proliferating in response to MDDC treated with SEB or virus. This is a
continuation of the experiment shown in Figure 2. Expression of IFN-c, IL-4, and/or TNF-a individually and in each double or triple combination
(Boolean gating) was determined in live, proliferating, singlet CD4+ T cells. (A, B) Time course of production of IFN-c and/or TNF-a by proliferating
CD4+ T cells proliferating in response to MDDC that were mock-treated or treated with SEB, or live or UV-inactivated rHRSV or IAV, using cells from
the same donor shown in Figure 2 A and B. (A) Total number of proliferating CD4+ T cells expressing IFN-c or TNF-a ˜ (B) Percentages of proliferating
CD4+ T cells expressing IFN-c and/or TNF-a, shown as pie charts. (C) Expression of IFN-c and/or TNF-a by live, proliferated CD4+ T cells in experiments
representing five of the eight donors shown in Figure 2 C. Values are expressed as percentages of total proliferated CD4+ T cells. The box plots show
the median (horizontal line) flanked by the 2
nd and 3
rd quartile. The outer bars show the range of values. No statistical differences were observed
between the treatments. (D) Comparison of the MFI of IFN-c (left panel) or TNF-a (right panel) by proliferating CD4+ T cells that were positive for only
the single cytokine versus those positive for both cytokines. The data are from the experiment in part C (cells from five donors). Statistical differences
are indicated by asterisks (Friedman test with Dunns post hoc test (see Materials and Methods); *=p#0.05.
doi:10.1371/journal.pone.0015017.g003
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was a modest but significant inhibitory effect by IAV at day 4.
Discussion
The ability of HRSV, HMPV and HPIV3 to re-infect
symptomatically throughout life without the need for significant
antigenic change has led to the widely held speculation that these
viruses, especially HRSV, can suppress or subvert the host
adaptive immune response, resulting in incomplete and inefficient
long-term immunity. A number of studies have addressed virus-
specific effects on APC and T lymphocyte responses in vitro, with
varied and inconsistent conclusions. The first such studies reported
that exposure of adult human peripheral blood mononuclear cells
(PBMC) to HRSV, IAV, and Sendai virus suppressed proliferation
in response to the non-specific mitogen phytohemagglutinin
(PHA), an effect that was attributed to the expression of CD54/
CD11a/CD18 (ICAM-1/LFA-1) and the interaction between
APC and T cells [43,44]. In 1992, Preston et al. [37] showed that
exposure of human cord blood mononuclear cells to HRSV
resulted in a reduction in proliferation in response to PHA. The
same study showed that exposure of adult PBMC to HRSV
reduced the proliferation response to Epstein-Barr virus antigen,
although this effect was not seen with all of the tested HRSV
strains. This effect was attributed to secreted IFN-a [45]. In
another study, HPIV3 was shown to reduce proliferation of adult
human PBMC in response to CD3-specific antibodies, an effect
that was attributed to increased production of IL-10 [46].
More recent studies have used increasingly more defined
conditions. Bartz et al. (2003) [41] generated human immature
DC in vitro from cord blood CD34+ stem cells and showed that in
presence of the toxic shock syndrome toxin-1 superantigen, HRSV
caused increased DC apoptosis and reduced expression of IFN-c
and increased expression of IL-4 without affecting proliferation.
Rothoeft et al. [38] reported reduced T cell proliferation in
response to HRSV stimulated CD34-derived DC, as well as
reduced IFN-c expression. De Graaf et al. [42] showed that
exposure of adult human MDDC to HRSV reduced SEB-
mediated proliferation and cytokine production by naı ¨ve alloge-
neic CD4+ T cells, which was attributed to a soluble MDDC
factor that was not identified but was not type I IFN. Chi et al. [36]
also showed that exposure of adult MDDC to HRSV resulted in
reduced proliferation of autologous CD4+ T cells in response to
SEB or cytomegalovirus antigen, whereas HPIV3 and IAV
controls resulted in less and no inhibition, respectively. The
inhibitory effect of HRSV was partially mediated by type I and
type III IFN [36]. Using human adult MDDC and allogeneic
CD4+ T lymphocytes, Guerrero-Plata et al. [47] showed that
HRSV inhibited the proliferation of allogeneic CD4+ T
lymphocytes to a greater extent than HMPV. However, Jones et
al. [48] did not observe HRSV-mediated inhibition of T cell
proliferation under comparable conditions. Schlender et al. [39]
showed that exposure to HRSV F protein expressed on the surface
of epithelial cells inhibited proliferation of T lymphocytes in
response to mitogen, but several of the co-culture studies described
above provided evidence that ruled out contact inhibition in the
observed inhibitory effects [36,38,42]. Thus, from these previous
studies, there was inconsistency in the effects of HRSV on DC and
on T cells and, in cases where inhibition or polarization was
observed, there were differences in the proposed mechanism.
To address the question of virus-specific suppression of CD4 T
cell function, we examined four viruses (HRSV, HMPV, HPIV3,
and IAV) side-by-side, whereas the majority of the studies noted
above examined a single virus, usually HRSV. While logistically
more difficult, comparing a greater number of viruses provided for
discrimination between effects that were unique to a particular
virus versus those that were common to all. Also, analyzing more
viruses and thus obtaining more comparisons for each individual
donor was useful, given the heterogeneity of responses from an
outbred human population. The ‘‘down-side’’ of our approach is
that these studies were time consuming and laborious, and the
donor-to-donor variability in human populations, and the
relatively large panel of viruses studied, would have necessitated
a high number of studies to reach statistical significance for the
more nuanced differences between viruses, and forced us to
interpret trends in differences.
We also used a more careful method of preparing virus. Viruses
were grown in Vero cells, which do not produce type I IFN, and
purified by sedimentation in sucrose gradients. We avoided the use
of high input MOI of virus, especially with HRSV, which was used
at an MOI of 10-20 or more in some studies [38,41,42], because
HRSV is physically unstable, typically is contaminated with co-
purified cellular membrane fragments, and has a high particle-to-
PFU ratio [49]. Thus, the use of a high MOI could result in a large,
disproportionate dose of viral antigen and cell contaminants. In
contrast to a number of studies that used allogeneic (unmatched)
cells, which results in T cell proliferation due to an MHC
incompatibility that is not relevant to viral infection, we used
autologous cells. Also, rather than relying on a single time point, we
evaluated kinetics and magnitude of T cell proliferation and
cytokine production. Another difference is that we (i) investigated
responses specific to each of these viruses, which primarily
represented stimulation of memory T cells from prior natural
infection, and which were dependent on antigen processing and
presentation by the DC, and (ii), using SEB as a model, addressed
the effect of viral infection of DC on secondary antigenic responses.
With regard to antigen-specific responses, CD4+ T cell
proliferation in response to MDDC exposed to rHRSV was less
than that to rHPIV3 and IAV and greater than to rHMPV, but
the differences were not significant. In addition, proliferation was
greater in response to MDDC exposed to live versus UV-
inactivated virus, indicating that, although we cannot rule out the
possibility of viral interference with CD4+ T cell proliferation, the
net effect of exposure to live virus was stimulatory rather than
inhibitory. The increased percentage of proliferating cells found in
IAV cultures might reflect the presence of more IAV-specific
CD4+ T cells at the beginning of the culture compared to the
frequency of T cells specific for the other viruses. However, the
Figure 4. Proliferation of CD4+ T cells during co-culture with virus-treated MDDC and SEB. (A) Time course of CD4+ T cell proliferation in
response to MDDC treated with rHRSV or IAV, or mock-treated, and co-cultured with SEB, using cells from a single donor. (B) Line graph of the data
from panel A. (C) Summary of CD4+ T cell proliferation on day 4 in experiments representing cells from six donors, in which MDDC were mock-
treated, or treated with each of the four live or inactivated virus, and co-cultured with SEB. Day 4 was used for comparison because the greatest
differences between cultures containing mock, rHRSV, or IAV stimulated MDDC were observed on this day. For comparison, using cells from three of
the six donors, mock-treated MDDC were co-cultured with autologous CD4+ T cells in the presence of SEB and IFN-b (75 IU per ml), or SEB and IL-28A
(0,5 mg/ml), or SEB and IL-29 (0.5 mg/ml), or SEB and a cocktail of IFN-b, IL-28, and IL-29 (75 IU per ml, 0,5 mg/ml, 0,5 mg/ml, respectively). The box
plots show the median (horizontal line) for each condition flanked by the 2
nd and 3
rd quartile. The outer bars show the range of values. Statistical
differences are indicated by lower case letters (below the x axis). Treatment groups that share a letter are not significantly different.
doi:10.1371/journal.pone.0015017.g004
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correlated well with the extent of MDDC maturation we observed
previously [30], as well as in additional MDDC maturation studies
(data not shown) in which IAV was slightly but not significantly
stronger in inducing MDDC maturation than rHPIV3, rHMPV,
and rHRSV. Thus, the trend of increasing T cell proliferation
responses in the order: rHMPV , rHRSV , rHPIV3 , IAV
might reflect the relative potency of each of these viruses to induce
MDDC maturation [30]. The sub-maximal nature of MDDC
maturation might represent insufficient stimulation rather than
virus-mediated inhibition, since a secondary LPS stimulus further
maturation to a similar final extent [30].
By day 7, the IFN-c and TNF-a cytokine expression profiles
were similar among the four viruses, with approximately the same
proportion of IFN-c single-positive or IFN-c/TNF-a double-
positive CD4+ T cells. This shows that MDDC stimulated by all
four viruses induced the same cytokines at similar levels with no
signs of inhibition or Th2- or Th17-biased responses.
The functionality of a protective T cell response depends on the
quality of the cytokine producing cell. Several recent studies have
shown that CD4+ T cells which are double-positive for IFN-c and
TNF-a produce thesecytokinesata higher levelcomparedtosingle-
positive cells [26,35,50,51]. This shows that these CD4+ T cells are
more strongly activated, and more likely to provide stronger helper
effects to CD8+ cells, leading to better protection [50,51]. In the
present study, we observed the same effect of increased cytokine
production from double-positive cells as compared to single-positive
cells. Thus, the proportion and number of IFN-c/TNF-a positive
cells was similar among the different viruses, providing no evidence
of a deficit specific to any particular virus.
The CD4+ T cell recall response to all viruses was Th1-biased
as characterized by the production of IFN-c and the low IL-4 and
IL-17 production by proliferating CD4+ T cells. This is offered
with the caveat that the MDDC were generated in vitro in the
presence of GM-CSF and IL-4, with the potential to bias the T cell
response, in particular by stimulating or inhibiting the Th2
pathway. While there have been many reports of plasticity among
CD4 T cell subsets, the data still points to a fair level of rigidity
among Th1 and Th2 subsets, compared, for example, to Th17
and Treg subsets. This suggests that our in vitro observations reflect
the level of Th1 responses to each of these viruses in vivo.
We also investigated whether any of the virus stimulated
MDDC inhibited T cell proliferation and cytokine production to
SEB, as a model of secondary infection that is independent of
virus-mediated differential effects on antigen uptake and presen-
tation pathways. Indeed, compared to their UV-inactivated
counterparts, rHRSV, rHPIV3 and IAV inhibited the CD4 T
cell response to SEB. However, this effect was transient, most
pronounced on day 4, and showed little or no difference between
live and UV-inactivated HRSV by day 6. The inhibitory effect was
relatively less for live rHRSV and rHMPV, whereas live IAV and
rHPIV3 induced a markedly stronger inhibition of proliferation
and IFN-c and TNF-a production by day 4 of co-culture.
The transient inhibition by live viruses in the SEB assay might
be explained by the anti-proliferative effect of type I interferon on
CD4+ T cells [52,53]. We detected higher type I interferon
expression levels in MDDC matured by rHPIV3 and influenza
virus compared to the other viruses ([30], and data not shown),
suggesting a possible role in inhibition of proliferation. We tested
this hypothesis in the present study by treating the MDDC/T cell
co-cultures with IFN-b in concentrations similar to those in
supernatants of rHPIV3-exposed MDDC [30] and found a
reduced proliferation in response to SEB, comparable to that of
SEB-treated MDDC/T cell co-cultures with rHPIV3-MDDC.
This supports the previous suggestion of Preston et al. [45] and
Chi et al. [36] that type I IFN plays a role in inhibiting T cell
responses to HRSV, and illustrates the importance of the local
cytokine environment [20] in the modulation of memory T cell
proliferation.
In summary, each of these common human respiratory
pathogens can affect the ability of MDDC to activate CD4+ T
cells. The more biologically relevant response, namely the
proliferation of virus-specific memory T cells, was somewhat less
for the paramyxoviruses compared to IAV. While this might make
a contribution to a trend of increased ease of re-infection, the
differences in proliferation did not rise to the level of statistical
significance. The modestly reduced paramyxovirus-specific prolif-
erative responses correlated with reduced levels of DC maturation
observed in previous studies, an effect that appeared to reflect a
lower level of stimulation rather than virus-mediated inhibition.
There was no obvious virus-specific bias to T cell polarization, and
cytokine production was not significantly different between viruses.
The non-specific proliferation response to SEB was lower for IAV
than for HRSV and the other viruses. These results suggest that
rHRSV-infected MDDC do not strongly and specifically inhibit
proliferation of CD4+ T cells. Thus, HRSV-specific effects on
DC/T cell interactions are unlikely to account for the ability of
HRSV to cause repeat infections during life.
Materials and Methods
Ethics statement
Elutriated monocytes and autologous CD4+ T lymphocytes
were obtained from healthy donors at the Department of
Transfusion Medicine of the National Institutes of Health, under
a protocol (99-CC-0168) approved by the Institutional Review
Board of the Clinical Center, NIH. Written informed consent was
obtained from all donors.
Virus stock preparation
Recombinant (r) HMPV (strain CAN97-83), rHRSV (strain A2)
and rHPIV3 (strain JS) were described previously [13,54,55]. The
rHMPV had previously been modified to silently remove tracts of
A and T residues in the SH gene that had been sites of
spontaneous mutations during passage in vitro [56]. Human IAV
was the non-recombinant wild-type H3N2 A/Udorn/72.
Figure 5. Cytokine expression by proliferating CD4+ T lymphocytes co-cultured with virus-treated MDDC and SEB. (A) Time course of
cytokine production by CD4+ T cells proliferating in response to MDDC that had been mock-treated or treated with live or UV-inactivated rHRSV, or
live IAV, and co-cultured in the presence of SEB, using cells from the same donor represented in Figure 4 A. The percentages of live proliferated cells
positive for IFN-c+, TNF-a+, IFN-c+ plus TNF-a+ and IFN-c+ plus TNF-a + plus IL-4+, are shown in the pie charts. (B) Percentage of live, proliferating
CD4+ T cells positive for IFN-c (left panel), TNF-a (middle panel), and IFN-c plus TNF-a (right panel) after four days of co-culture with SEB and MDDC
treated with each of the four live or UV-inactivated viruses or mock treatment, using cells from the same six donors shown in Figure 4 C. As a control,
one co-culture for each donor containing mock-treated MDDC also contained 75 IU/ml IFN-b in addition to SEB. The box plots show the median
(horizontal line) flanked by the 2
nd and 3
rd quartile. The outer bars show the range of values. (C) Comparison of the MFI of IFN-c (left panel) or TNF-a
(right panel) by proliferating CD4+ T cells that were positive for only the single cytokine versus those positive for both cytokines. The data are from
the experiment in part B (cells from six donors). Treatments sharing the same lowercase letter do not differ significantly.
doi:10.1371/journal.pone.0015017.g005
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cells (CCL-81, ATCC, Manassas, VA) were infected with low-
passage rHMPV, rHRSV, rHPIV3 or IAV at an input MOI of
approximately 0.1 PFU/cell, and after 6 to 8 days, the
supernatants were collected and clarified by centrifugation, and
virus was collected by centrifugation on discontinuous sucrose
gradients [30]. Since initial studies had indicated that the presence
of sucrose interfered with MDDC maturation (results not shown),
gradient purified viruses were pelleted by centrifugation to remove
sucrose, as described [30]. Virus pellets were resuspended in
Advanced RMPI (aRPMI) 1640 supplemented with 2 mM L-
glutamine, and aliquots were snap frozen and stored at 280uC
until use. Virus titers were determined by immunoplaque assay as
described previously [54]. UV-inactivated viruses were included as
controls and were prepared using a Stratalinker UV cross-linker
(Agilent, Santa Clara, CA) at 0.5 J/cm
2, with inactivation
monitored by plaque assay.
Generation of immature MDDC and purification of
autologous CD4+ T lymphocytes
Elutriated monocytes and autologous CD4+ T lymphocytes
were obtained from healthy donors at the Department of
Transfusion Medicine of the National Institutes of Health, under
a protocol (99-CC-0168) approved by the IRB of the Clinical
Center, NIH. Written informed consent was obtained from all
donors. As previously described [30], monocytes were subjected to
CD14+ positive sorting on an AutoMACS separator (Miltenyi
Biotec, Auburn CA), and were cultured in the presence of
recombinant human IL-4 (R&D Systems, Minneapolis, MN) and
recombinant human granulocyte-macrophage colony-stimulating
factor (GM-CSF; LeukineH, Bayer Healthcare, Wayne, NJ) for 7
days to generate immature MDDC. Elutriated T lymphocytes
were purified from contaminating red blood cells by centrifugation
on Ficoll (Lymphocyte Separation Medium; Cellgro, Manassas,
VA) followed by treatment with ACK lysis buffer (Lonza,
Walkersville, MD) to lyse erythrocytes. T lymphocytes were frozen
at 280uC. Prior to use, the cells were thawed, incubated
overnight, and subjected to positive sorting on an AutoMACS
separator using magnetic microbeads coated with a CD4 specific
monoclonal antibody (Miltenyi Biotec) to obtain CD4+ T cells.
The purity of the CD4+ T lymphocytes based on the cell surface
expression of CD3 and CD4 proteins was confirmed by flow
cytometry to be $96%.
Treatment of MDDC with virus or controls
Immature MDDC were labeled with the far-red cell tracer 7-
hydroxy-9H-(1,3-dichloro-9,9-dimethylacridin-2-one) (DDAO; In-
vitrogen, Frederick, MD). After 15 min incubation of MDDC in
medium with 1.5 mM DDAO at room temperature, cells were
quenched on ice using 5 volumes of aRPMI supplemented with
5% heat-inactivated human serum (Gemini Bio-Products, West
Sacramento, CA) and extensively washed with aRPMI with 10%
human serum. The DDAO labeled immature MDDC were then
washed in aRPMI with 10% heat-inactivated fetal bovine serum
(FBS), and seeded in 12-well plates at 6610
5 cells per well and
were (i) keep mock-stimulated, (ii) infected for 4 to 6 h with live
virus at an input MOI of 3 PFU/cell, (iii) with an equivalent
amount of UV-inactivated virus, or (iv) incubated with 1 mg/ml of
the superantigen SEB (Sigma, St Louis, MO), a strong inducer of
CD4+ T cell proliferation. All inoculations or stimulations were
performed in complete medium (aRPMI supplemented with 10%
heat-inactivated FBS, 2 mM L-glutamine, 200 U/ml penicillin
and 200 mg/ml streptomycin) at 37uCi n5 %C O 2.
Co-culture of stimulated MDDC with autologous CD4+ T
cells
After four to six h of stimulation, MDDC were extensively
washed with complete medium and the absence of remaining
infectious virus particles in the MDDC suspensions was confirmed
by plaque assay as described above. To monitor CD4+ T cell
proliferation by flow cytometry, autologous purified CD4+ T cells
were labeled by incubation with the cell tracer carboxyfluorescein
succinimidyl ester (CFSE, 1 mM) for 10 min at 37uC. Cells were
quenched using medium with 5% human serum for 5 min on ice
and extensively washed with complete medium. DDAO-labeled
stimulated MDDC were co-cultured with CFSE-labeled CD4+ T
lymphocytes at a ratio of one MDDC for ten CD4+ T
lymphocytes for 1 to 7 days at 37uCi n5 %C O 2.
In some experiments (Figure 4 and 5), mock-treated MDDC, live
viruses-treated MDDC or UV-viruses treated MDDC were co-
cultured with autologous CD4+ T cells in the presence of SEB
(50 ng/ml).Inaddition,mock-treatedMDDCwereco-culturedwith
autologous CD4+ T cells in the presence of (i) SEB (50 ng/ml), (ii)
SEB plus IFN-b (75 IU/ml), (iii) SEB plus IL-28A (0.5 mg/ml), (iv)
SEB plus IL-29 (0.5 mg/ml), or (v) SEB plus a cocktail of IFN-b,I L -
28, and IL-29 (75 IU per ml, 0.5 mg/ml, 0.5 mg/ml, respectively).
Flow cytometry
Co-cultures were incubated for 6 h at 37uC with 20 ng/ml
Phorbol myristate acetate (PMA), 1 mM ionomycin and 10 mg/ml
brefeldin A to prepare for intracellular cytokine staining. Cells
were then harvested and stained using live/dead fixable blue dead
cell stain (Invitrogen) for 30 min at 4uC to discriminate between
live and dead cells by flow cytometry. The cells were fixed and
permeabilized according to the manufacturers instructions using
the perm/wash buffer kit (BD Biosciences, San Jose, CA), blocked
with milk saponin (0.1% saponin, 0.1% bovine serum albumin,
5% non-fat dried milk in PBS) for 30 min and immunostained
according to previously published protocols [57] with anti-human
mAbs at concentrations previously determined to be optimal by
titration. The following anti human monoclonal antibodies were
obtained from BD biosciences unless otherwise stated: CD3
allophycocyanin-cychrome 7 (APCcy7), clone SK7; IFN-c phyco-
erythrin-cychrome 7 (PECy7), clone 4S.B3; IL-4 phycoerythrin
(PE), clone MP4-25D2; TNF-a biotin, (clone Mab11) followed by
QDot605-streptavidin (Invitrogen); and in some experiments (not
shown), IL10 (APC) clone JES3-19F1, IL-17A fluorescein
isothiocyanate (FITC) clone eBio64DEC17 (eBioscience, San
Diego, CA). The steps in the flow cytometry analysis are shown
in Figure 1. At least 30,000 events were acquired using a BD
LSRII flow cytometer (BD Biosciences).
In addition, in some experiments, we determined if the
proliferating CD4+ T cells arose from naı ¨ve versus virus specific
memory cells. Virus stimulated MDDC were co-cultivated with
CFSE stained autologous CD4+ cells. At day 4 and 7, cells were
harvested and stained with live/dead fixable violet dead cell stain
(Invitrogen) to discriminate between live and dead cells, and with
an antibody specific to CD3 (APCcy7, clone SK7) to identify T
lymphocytes. To discriminate between naı ¨ve and memory CD4+
T cells, cells were stained with antibodies to CD45RA (PE, clone
HI100), and to CD45RO (PEcy5, clone UCHL1), respectively. To
discriminate between central memory and effector memory CD4+
T cells, co-cultures were stained for CCR7 (PEcy7, clone 2H4).
CCR7 is expressed on central memory but not on effector memory
CD4+ T cells [58].
Compensation was performed automatically using single color
antibody capture beads (BD biosciences) for each antibody. Due to
cell number limitations, settings and gating were adjusted using
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with the same staining panel of antibodies and cell numbers as
used in the present study. The gating was performed generously
(i.e. far enough from the negative populations to not include
negative events in the positive gates). The gating for cytokines was
kept consistent between experiments as rainbow beads were used
to adjust each photomultiplier tube voltage to the same median
fluorescence for all experiments as previously described [35,59,60].
In addition, fluorescent minus one controls were included in one
experiment presented in the present study. In each experiment
and each fluorescence minus one control, no cells negative for a
given cytokine were ever found in the positive gate. Live/dead
staining, forward scatter height, forward scatter area, side scatter,
DDAO, CD3, CFSE, and expression of IFN-c, IL-4, IL-17 and
TNF-a were analyzed using FlowJo version 8.8.2 software (Tree
Star, Inc., Ashland, OR). Pie charts were generated using SPICE
version 4.2.3, a data mining and visualization software for
multicolor flow cytometry, written and kindly provided by Mario
Roederer and Joshua Nozzi of the Vaccine Research Center at the
National Institute of Allergy and Infectious Diseases.
Statistical analysis
Data sets were assessed for significance using parametric one-
way repeated measures ANOVA with the Tukey post hoc tests for
normally distributed data sets or the non-parametric Friedman test
with Dunns post hoc test. A log10 transformation was applied to
data sets when necessary to obtain equal standard deviation
among groups, a necessary requirement of both tests. Statistics
were performed using Prism, version 5 ( 1992-2008 GraphPad
Software, Inc, San Diego, CA). Data were only considered
significant at P#0.05.
Supporting Information
Figure S1 Memory phenotype of the proliferating CD4+
T cells. Proliferating CD4+ T cells (CFSE diluted T cells) were
analyzed for naı ¨ve or memory markers. MDDC derived from one
donor were stimulated with the indicated virus at an MOI of 3 and
co-cultivated with autologous CD4+ T cells at the ratio of 1
MDDC for 10 CD4+ T cells. The phenotype of the proliferating
CD4+ T cells was evaluated on day 4, corresponding to the time of
detection of the first proliferating cells (see Figure 2 A), and on day
7, corresponding to the time point when proliferation and cytokine
production was evaluated for multiple donors (see Figure 2 C, and
Figure 3 C and D). The percentage of live proliferated cells
positive for CD45RA, CD45RO and CCR7 are indicated.
(TIF)
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